Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism - PubMed (original) (raw)

Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism

Yun Zhang et al. Hum Gene Ther. 2003.

Abstract

Brain gene-targeting technology is used to reversibly normalize tyrosine hydroxylase (TH) activity in the striatum of adult rats, using the experimental 6-hydroxydopamine model of Parkinson's disease. The TH expression plasmid is encapsulated inside an 85-nm PEGylated immunoliposome (PIL) that is targeted with either the OX26 murine monoclonal antibody (MAb) to the rat transferrin receptor (TfR) or with the mouse IgG2a isotype control antibody. TfRMAb-PIL, or mIgG2a-PIL, is injected intravenously at a dose of 10 microg of plasmid DNA per rat. TfRMAb-PIL, but not mIgG2a-PIL, enters the brain via the transvascular route. The targeting TfRMAb enables the nanocontainer carrying the gene to undergo both receptor-mediated transcytosis across the blood-brain barrier (BBB) and receptor-mediated endocytosis into neurons behind the BBB by accessing the TfR. With this approach, the striatal TH activity ipsilateral to the intracerebral injection of the neurotoxin was normalized and increased from 738 +/- 179 to 5486 +/- 899 pmol/hr per milligram of protein. The TH enzyme activity measurements were corroborated by TH immunocytochemistry, which showed that the entire striatum was immunoreactive for TH after intravenous gene therapy. The normalization of striatal biochemistry was associated with a reversal of apomorphine-induced rotation behavior. Lesioned animals treated with the apomorphine exhibited 20 +/- 5 and 6 +/- 2 rotations/min, respectively, after intravenous administration of the TH plasmid encapsulated in mIgG2a-PIL and TfRMAb-PIL. These studies demonstrate that it is possible to normalize brain enzyme activity by intravenous administration and nonviral gene transfer.

PubMed Disclaimer

Cited by

shRNA and siRNA delivery to the brain.
Pardridge WM. Pardridge WM. Adv Drug Deliv Rev. 2007 Mar 30;59(2-3):141-52. doi: 10.1016/j.addr.2007.03.008. Epub 2007 Mar 16. Adv Drug Deliv Rev. 2007. PMID: 17434235 Free PMC article. Review.
Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.
Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M. Dostalek M, et al. Clin Pharmacokinet. 2013 Feb;52(2):83-124. doi: 10.1007/s40262-012-0027-4. Clin Pharmacokinet. 2013. PMID: 23299465 Review.
Advances in Intrathecal Nanoparticle Delivery: Targeting the Blood-Cerebrospinal Fluid Barrier for Enhanced CNS Drug Delivery.
Madadi AK, Sohn MJ. Madadi AK, et al. Pharmaceuticals (Basel). 2024 Aug 15;17(8):1070. doi: 10.3390/ph17081070. Pharmaceuticals (Basel). 2024. PMID: 39204177 Free PMC article. Review.
A Historical Review of Brain Drug Delivery.
Pardridge WM. Pardridge WM. Pharmaceutics. 2022 Jun 16;14(6):1283. doi: 10.3390/pharmaceutics14061283. Pharmaceutics. 2022. PMID: 35745855 Free PMC article. Review.
Gene Therapy: The Next-Generation Therapeutics and Their Delivery Approaches for Neurological Disorders.
Paul A, Collins MG, Lee HY. Paul A, et al. Front Genome Ed. 2022 Jun 22;4:899209. doi: 10.3389/fgeed.2022.899209. eCollection 2022. Front Genome Ed. 2022. PMID: 35832929 Free PMC article. Review.

Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism - PubMed (original) (raw)